Market potential Presbyopia addressing implants offer a niche aesthetic and clinical advantage; target ophthalmology clinics and eye centers focusing on refractive surgery to expand Raindrop Near Vision Inlay adoption in markets with FDA-approved status.

Strategic funding Leverage the existing strong funding history and high investor interest (JJDC participation) to approach strategic partnerships with larger medical device companies for distribution, co-development, or licensing deals to scale commercialization.

Clinical safety positioning Emphasize rigorous patient screening and post-market safety data to differential from competing vision correction options; offer training and support for surgeons on patient selection and management of potential adverse events to reduce installation reluctance.

Expansion channels Utilize digital and omnichannel tools (AdRoll, LiveChat, WhatsApp) to reach ophthalmologists and clinics; propose turnkey marketing and patient education packages to accelerate referrals and patient consultations.

Adjacent markets Explore integration with broader refractive surgery portfolios and corneal therapies; identify opportunities with larger device makers (STAAR, Alcon, Bausch & Lomb sized players) for co-branding or inclusion in comprehensive presbyopia treatment suites.